show help

Karlsson A

Author page

This page provides a summary of the entries in Polbase associated with this author.

The publication history graph presents the number of publications in Polbase by this author over time.

The polymerase chart indicates which polymerases this author has published on.

Polbase automatically discovers many polymerase papers as they are published. Some relevant papers are not included because the algorithm is designed to reduce background. Please contribute to polbase by adding your missing DNA polymerase papers.

Help icons:

The show help symbol in the upper-right corner of the page links to this help text. The question mark icon is used everywhere to indicate that help is available.

Missing references?

Publications:

Title Authors Year Journal
Recent advances in thymidine kinase 2 (TK2) inhibitors and new perspectives for potential applications. Karlsson A 2012 Current pharmaceutical design
The phenylmethylthiazolylthiourea nonnucleoside reverse transcriptase (RT) inhibitor MSK-076 selects for a resistance mutation in the active site of human immunodeficiency virus type 2 RT. Karlsson A 2004 Journal of virology
Exploitation of the low fidelity of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase and the nucleotide composition bias in the HIV-1 genome to alter the drug resistance development of HIV. Karlsson A 2001 Journal of virology
Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1. Karlsson A 1997 Journal of virology
Reverse transcriptase fidelity and HIV-1 variation. Karlsson A 1997 Science (New York, N.Y.)
Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2',3'-dideoxy-3'-thiacytidine. Karlsson A 1996 Molecular pharmacology
Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication. Karlsson A 1996 Molecular pharmacology
Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e., TSAO derivatives). Karlsson A 1995 Proceedings of the National Academy of Sciences of the United States of America
Activity of various thiocarboxanilide derivatives against wild-type and several mutant human immunodeficiency virus type 1 strains. Karlsson A 1995 Antiviral research
Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720. Karlsson A 1994 Journal of virology
Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C-->C181I)RT HIV-1 mutants. Karlsson A 1994 Proceedings of the National Academy of Sciences of the United States of America
Sensitivity of (138 Glu-->Lys) mutated human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) to HIV-1-specific RT inhibitors. Karlsson A 1994 Biochemical and biophysical research communications
Human immunodeficiency virus type 1-specific [2',5'-bis-O-(tert- butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"- oxathiole-2",2"-dioxide)-purine analogues show a resistance spectrum that is different from that of the human immunodeficiency virus type 1-specific non-nucleoside analogues. Karlsson A 1993 Molecular pharmacology
Human immunodeficiency virus type 1 drug-resistance patterns with different 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives. Karlsson A 1993 Molecular pharmacology
HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase. Karlsson A 1993 Virology
Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy. Karlsson A 1993 Journal of virology
Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro- 5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)]-beta-D-pentofurano syl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors. Karlsson A 1993 Proceedings of the National Academy of Sciences of the United States of America
Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus. Karlsson A 1993 Virology
All Authors

Using Polbase tables:

Sorting:

Tables may be sorted by clicking on any of the column titles. A second click reverses the sort order. <Ctrl> + click on the column titles to sort by more than one column (e.g. family then name).

Filtering:

It is also possible to filter the table by typing into the search box above the table. This will instantly hide lines from the table that do not contain your search text.